Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

In vitro activity of cefiderocol in combination with new β-lactam/β-lactamase inhibitor combinations (βL-βLICs) against multidrug resistant KPC-producing Klebsiella pneumoniae

The Journal of Antibiotics volume 76, pages 682–688 (2023)Cite this article

Subjects

βL-βLIC New β-lactam/β-lactamase inhibitor combinations (βL-βLICs) have been recently developed for the treatment of difficult-to-treat (DTR) infections caused by multi-drug-resistant (MDR) microorganisms. Although the new βL-βLICs represent a promising effective option for treatment of DTR infections due to carbapenemase-producing Enterobacterales (CPE), the emergence of strains resistant to these molecules poses further considerations in their clinical use [1]. Recently, a novel siderophore cephalosporin, cefiderocol (CFD), has been developed for treatment of challenging DTR infections due to MDR pathogens. Although CFD exerts potent in vitro activity against most MDR Gram-negative microorganisms, recent studies reported the increase of CFD-resistant strains thus limiting its clinical impact [2, 3]. In this context, combination antimicrobial treatments have been proposed to overcome the emergence of DTR pathogens [4].

Aim of this study was to evaluate the in vitro activity of CFD in association with ceftazidime/avibactam (CAZ-AVI), meropenem/vaborbactam (MER/VAB), and/or imipenem/relebactam (IMI-REL) and fosfomycin (FOS) against a collection of MDR KPC-producing K. pneumoniae (KPC-Kp) clinical isolates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

References

  1. Gaibani P, Giani T, Bovo F, Lonbardo D, Amadesi S, Lazzarotto T, et al. Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in Gram-negative MDR bacilli: molecular mechanisms and susceptibility testing. Antibiotics. 2022;11:628.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics. 2022;11:723.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gaibani P, Amadesi S, Lazzarotto T, Ambretti S. Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient. J Glob Antimicrob Resist. 2022;30:262-264.

  4. Bavaro DF, Belati A, Diella L, Stufano M, Romanelli F. Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives. Antibiotics. 2021;10:652.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gaibani P, Crovara-Pesce C, Lazzarotto T, Pea F, Ambretti S. Evaluation of synergistic activity of fosfomycin in combination with novel ß-lactams/ß-lactamase inhibitor combinations (βL-βLICs) against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Antimicrob Agents. 2022;60:106671.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by Italian Ministry of Health (Ricerca Finalizzata, Giovani Ricercatori, GR-2018-12367572).

Author information

Authors and Affiliations

  1. Division of Microbiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    Paolo Gaibani, Tiziana Lazzarotto & Simone Ambretti

  2. University of Bologna, Bologna, Italy

    Tiziana Lazzarotto, PierLuigi Viale & Simone Ambretti

  3. Division of Infectious Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

    PierLuigi Viale

Authors
  1. Paolo Gaibani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiziana Lazzarotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. PierLuigi Viale
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Simone Ambretti
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The authors contributions was PG conceptualized, wrote, and edited the article, and prepared the figures. TL, SA, and PLV supervised the study and edited the article.

Corresponding author

Correspondence to Paolo Gaibani.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gaibani, P., Lazzarotto, T., Viale, P. et al. In vitro activity of cefiderocol in combination with new β-lactam/β-lactamase inhibitor combinations (βL-βLICs) against multidrug resistant KPC-producing Klebsiella pneumoniae. J Antibiot 76, 682–688 (2023). https://doi.org/10.1038/s41429-023-00653-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41429-023-00653-8

Search

Advanced search

Quick links